Abstract
Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.
| Original language | English |
|---|---|
| Journal | Current Opinion in Investigational Drugs |
| Volume | 6 |
| Issue number | 4 |
| Pages (from-to) | 419-26 |
| Number of pages | 7 |
| ISSN | 1472-4472 |
| Publication status | Published - 2005 |
